Achieving blood pressure control targets in hypertensive patients of rural China - a pilot randomized trial.

Trials
Xiao Huanginvestigators of intensive BP control in China

Abstract

This study aimed to test the feasibility and titration methods used to achieve specific blood pressure (BP) control targets in hypertensive patients of rural China. A randomized, controlled, open-label trial was conducted in Rongcheng, China. We enrolled 105 hypertensive participants aged over 60 years, and who had no history of stroke or cardiovascular disease. The patients were randomly assigned to one of three systolic-BP target groups: standard: 140 to < 150 mmHg; moderately intensive: 130 to < 140 mmHg; and intensive: < 130 mmHg. The patients were followed for 6 months. The optimal target for systolic blood pressure (SBP) lowering is still uncertain worldwide and such information is critically needed, especially in China. However, in China the rates of awareness, treatment and control are only 46.9%, 40.7%, and 15.3%, respectively. It is challenging to achieve BP control in the real world and it is very important to develop population-specific BP-control protocols that fully consider the population's characteristics, such as age, sex, socio-economic status, compliance with medication, education level, and lifestyle. This randomized trial showed the feasibility and safety of the titration protocol to achieve desirable SBP t...Continue Reading

Associated Clinical Trials

References

Nov 21, 2002·JAMA : the Journal of the American Medical Association·Jackson T WrightUNKNOWN African American Study of Kidney Disease and Hypertension Study Group
Dec 5, 2003·Journal of Hypertension·Christopher J BulpittUNKNOWN Hypertension in the Very Elderly Trial Working Group
Mar 17, 2010·The New England Journal of Medicine·William C CushmanFaramarz Ismail-Beigi
Jun 10, 2010·Hypertension·Toshio OgiharaUNKNOWN Valsartan in Elderly Isolated Systolic Hypertension Study Group
Mar 17, 2015·JAMA : the Journal of the American Medical Association·Yong HuoUNKNOWN CSPPT Investigators
Nov 10, 2015·The New England Journal of Medicine·UNKNOWN SPRINT Research GroupWalter T Ambrosius
Mar 15, 2016·JAMA Internal Medicine·Sarah LewingtonUNKNOWN China Kadoorie Biobank Consortium
Apr 5, 2016·The New England Journal of Medicine·Eva M LonnUNKNOWN HOPE-3 Investigators
Jul 1, 2016·Clinical and Experimental Hypertension : CHE·Zhilai ChenHuijun Liu
Sep 10, 2017·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·J D Spence
Feb 17, 2018·Circulation·Zengwu WangUNKNOWN China Hypertension Survey Investigators

❮ Previous
Next ❯

Citations

Aug 23, 2020·Stroke and Vascular Neurology·J David Spence

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT02817503

Software Mentioned

Epidata
SPRINT
Empower R

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.